|
|
Vaccine Detail
|
NY-ESO-1/LAGE-1 Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: NY-ESO-1/LAGE-1 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007143
- Type: Multipeptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: NY-ESO-1, CTAG2
- CTAG1B
gene engineering:
- CTAG2
gene engineering:
- Preparation: The LAGE-1–, NY-ESO-1–, and HIV-derived peptides were synthesized using standard Fmoc chemistry. Lyophilized peptides were dissolved in 100% DMSO at a concentration of 2 mg/ml and stored at −20°C until use (Kudela et al., 2011).
- Description: This is for Prostate Cancer (NCT00616291).A cancer vaccine containing HLA class I- and II-binding peptides derived from the NY-ESO-1/LAGE-1 cancer/testis antigen with potential immunostimulatory and antineoplastic activities. Upon administration, NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine may induce a cytotoxic immune response against tumor cells that over-express NY-ESO-1/LAGE-1. Rarely expressed by normal cells, the NY-ESO-1/LAGE-1 cancer/testis antigen has been shown to be preferentially expressed on the surface of some cancer cell types (Kudela et al., 2011; NCIT_C74066).
|
| Host Response |
|
|
| References |
Kudela et al., 2011: Kudela P, Sun Z, Fourcade J, Janjic B, Kirkwood JM, Maillere B, Zarour HM. Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1. Journal of immunology (Baltimore, Md. : 1950). 2011; 186(1); 312-322. [PubMed: 21131422].
NCIT_C74066: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74066]
NCT00616291: Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer [https://clinicaltrials.gov/ct2/show/NCT00616291]
|
|
